Updated on 19 February 2014
Singapore: AstraZeneca (AZ) has entered into a collaboration with the Cancer Research UK (CRUK) Cambridge Institute to temporarily locate up to 60 AZ scientists in the Institute, in an attempt to accelerate medical technology innovation - with a particular emphasis on finding breakthrough treatments for cancer.
The CRUK Cambridge Institute, which is a part of the University of Cambridge, is located on the Cambridge Biomedical Campus. AstraZeneca UK will launch its global strategic R&D center and corporate headquarters at this site. AstraZeneca researchers will work alongside counterparts at the CRUK Cambridge Institute's state-of-the-art laboratories for up to three years.
The co-location of researchers will also support the existing projects between AstraZeneca, the CRUK Cambridge Institute and other organizations including the University of Cambridge, Department of Oncology, the MRC Cancer Unit and Addenbrooke's Hospital on a number of clinical and pre-clinical oncology projects.
Mr Susan Galbraith, head, Oncology Innovative Medicines Unit, AstraZeneca, said that, "We're thrilled with this early opportunity to join the vibrant Cambridge biomedical community. This will enable AstraZeneca and CRUK Cambridge Institute scientists to work side-by-side, sharing their respective world-class oncology expertise and building on the momentum of our existing research in this vital area."
Professor Simon Tavaré, director, CRUK Cambridge Institute, welcomed the opportunity for further connections with AstraZeneca, and said, "The CRUK Cambridge Institute is keen to develop new research directions with pharma and biotech."